DaVita Inc. operates outpatient kidney dialysis centers and provides comprehensive renal care services for patients with end-stage renal disease (ESRD) in the United States. The company's core business centers on operating dialysis facilities that deliver hemodialysis and peritoneal dialysis treatments, supplemented by clinical laboratory services that perform routine and physician-prescribed tests for dialysis patients. Beyond in-center dialysis, DaVita offers home-based hemodialysis services, hospital inpatient dialysis, and integrated care management services structured around risk-based payment arrangements. The company also operates a transplant software division and provides physician services and clinical research programs related to kidney disease management.
DaVita's revenue streams derive primarily from kidney dialysis services and related ancillary services delivered through its network of outpatient treatment centers, complemented by laboratory services and integrated care arrangements. The company generates revenue through both fee-for-service models and value-based contracts with payers.
The company operates with approximately 78,000 full-time employees across its U.S. operations. DaVita was incorporated in Delaware in 1994 and maintains its headquarters in Denver, Colorado. The company is publicly traded on the New York Stock Exchange.
Fiscal years are as reported by the company and may not align with the calendar year. For example, Apple's FY 2024 ends in September 2024.
| Fiscal Year | EPS Diluted | EPS Basic | YoY | |
|---|---|---|---|---|
| 2025 | $9.84 | $10.06 | -8.3% | |
| 2024 | $10.73 | $11.02 | +44.6% | |
| 2023 | $7.42 | $7.62 | +26.8% | |
| 2022 | $5.85 | $6.03 | -34.3% | |
| 2021 | $8.90 | $9.30 | +493.3% | |
| 2020 | $1.50 | $1.56 | -20.2% | |
| 2019 | $1.88 | $1.89 | +308.9% | |
| 2018 | $-0.90 | $-0.90 | -154.9% | |
| 2017 | $1.64 | $1.66 | +105.0% | |
| 2016 | $0.80 | $0.81 | +2766.7% | |
| 2015 | $-0.03 | $-0.03 | -103.1% | |
| 2014 | $0.96 | $0.98 | -3.0% | |
| 2013 | $0.99 | $1.01 | -34.4% | |
| 2012 | $1.51 | $1.54 | -3.2% | |
| 2011 | $1.56 | $1.59 | +122.9% | |
| 2010 | $0.70 | $0.71 | -82.8% | |
| 2009 | $4.06 | $4.08 | — |
| Report Date | Filed | Accession Number | |
|---|---|---|---|
| 2025-12-31 | 2026-02-11 | 0000927066-26-000012 | SEC ↗ |
| 2024-12-31 | 2025-02-13 | 0000927066-25-000012 | SEC ↗ |
| 2023-12-31 | 2024-02-14 | 0000927066-24-000013 | SEC ↗ |
| 2022-12-31 | 2023-02-22 | 0000927066-23-000011 | SEC ↗ |
| 2021-12-31 | 2022-02-11 | 0000927066-22-000012 | SEC ↗ |
| 2020-12-31 | 2021-02-12 | 0000927066-21-000008 | SEC ↗ |
| 2019-12-31 | 2020-02-21 | 0000927066-20-000014 | SEC ↗ |
| 2018-12-31 | 2019-02-22 | 0000927066-19-000025 | SEC ↗ |
| 2017-12-31 | 2018-02-23 | 0000927066-18-000030 | SEC ↗ |
| 2016-12-31 | 2017-02-24 | 0001564590-17-002409 | SEC ↗ |
| 2015-12-31 | 2016-02-26 | 0001564590-16-013587 | SEC ↗ |